Lingzhi Zhong | Medicine | Best Researcher Award

Dr. Lingzhi Zhong | Medicine | Best Researcher AwardΒ 

Dr. Lingzhi Zhong PLA General Hospital, China.

Dr. Lingzhi Zhong is an Assistant Research Fellow and Lecturer at the PLA General Hospital πŸ₯. She holds a Ph.D. in Pathology and Physiology from Jilin University πŸŽ“. Her research specializes in tissue repair and regenerative medicine 🧬. With over ten peer-reviewed publications, several patents, and editorial roles, she has made remarkable strides in wound healing innovations πŸ’‘. Dr. Zhong is also a member of the Microcirculation Committee and continues to drive impactful biomedical research with passion and precision πŸ”¬βœ¨.

🌟 Professional Profile

Orcid Profile

πŸŽ“ Early Academic Pursuits

Lingzhi Zhong began her academic journey with a Ph.D. in Pathology and Physiology from Jilin University School of Basic Medicine. During her formative years, she cultivated a strong foundation in medical sciences, with a growing interest in tissue repair and regenerative medicine. Her rigorous academic training laid the groundwork for a prolific research career that would later evolve into impactful scientific contributions.

πŸ’Ό Professional Endeavors

Dr. Zhong currently serves as an Assistant Research Fellow and Lecturer at the Department of Basic Medicine, PLA General Hospital. With over a decade of research experience, she is actively involved in the scientific community, both as a lecturer and investigator. Her professional trajectory also includes editorial roles, contributing as a board member and associate editor for esteemed academic publications. Her academic service underscores her dedication to both teaching and research leadership.

πŸ”¬ Contributions and Research Focus On MedicineΒ 

Dr. Zhong’s research centers around wound healing, tissue regeneration, and anti-scarring innovations. One of her notable breakthroughs includes the reprogramming of fibroblasts into endothelial cells using forskolin, a discovery funded by the Youth Project of the National Natural Science Foundation of China. She has also explored the potential of arsenic compounds in inhibiting scar formationβ€”an unprecedented approach in wound repair research. Her multi-faceted innovations bridge chemistry, biology, and medicine.

🌍 Impact and Influence

Her work has made a tangible impact on regenerative medicine, advancing strategies for scar reduction and chronic wound healing. The development of composite dressings and chitosan-based therapeutics reflects her commitment to clinical translation and improved patient outcomes. She has co-authored over ten SCI-indexed publications, each contributing to a better understanding of biological healing processes and therapeutic design.

πŸ† Awards and Honors

Dr. Zhong has earned recognition for her pioneering research in regenerative medicine and wound care. Her nomination for the Best Researcher Award underlines her innovative edge and dedication to biomedical science. Her editorial appointments and participation in professional societies like the Microcirculation Committee of the Society of Integrated Traditional Chinese and Western Medicine further reinforce her respected standing in the scientific community.

πŸ“š Books, Patents, and Innovation

Her contributions extend beyond journal articles. Dr. Zhong is currently co-authoring a book titled “Progress in Life Sciences”. She also holds three patents in advanced biomedical technologies:

  1. Composite dressing for skin healing

  2. Chemical induction of dermal fibroblasts

  3. Chitosan-taurine microbeads for scar reduction

These innovations demonstrate her translational research impact, turning lab discoveries into therapeutic applications.

πŸš€ Legacy and Future Contributions

Lingzhi Zhong is at the forefront of translational regenerative medicine. Her work continues to inspire new methods for scar-free healing, and she remains dedicated to developing novel bioactive delivery systems. With continued research, editorial leadership, and interdisciplinary collaboration, Dr. Zhong is poised to make lasting contributions to science and human health.

πŸ“šPublications Top Notes

  1. 🧴 Forskolin-loaded carboxymethyl chitosan and silk nanofiber hydrogels composite scaffolds improve skin regeneration
    International Journal of Biological Macromolecules, 2025

  2. 🧬 Chitosan-taurine nanoparticles cross-linked carboxymethyl chitosan hydrogels facilitate both acute and chronic diabetic wound healing
    International Journal of Biological Macromolecules, 2024

  3. 🧠 Potential pre-activation strategies for improving therapeutic efficacy of mesenchymal stem cells: current status and future prospects
    Stem Cell Research & Therapy, 2022

  4. 🐷 Characterization of the Skin Bacteriome and Histology Changes in Diabetic Pigs
    The International Journal of Lower Extremity Wounds, 2022

  5. 🌿 Promotive effects of four herbal medicine ARCC on wound healing in mice and human
    Health Science Reports, 2022

  6. πŸ”¬ A New Target of the Four-Herb Chinese Medicine for Wound Repair Promoted by Mitochondrial Metabolism Using Protein Acetylation Analysis
    Medical Science Monitor, 2022

  7. πŸ”₯ Macrophage Related Chronic Inflammation in Non-Healing Wounds
    Frontiers in Immunology, 2021

  8. 🧫 Biological approaches for hypertrophic scars
    International Wound Journal, 2020

  9. 🩹 Chitosan/LiCl composite scaffolds promote skin regeneration in full-thickness loss
    Science China Life Sciences, 2020

  10. πŸ§ͺ Sustained release of inhibitor from bionic scaffolds for wound healing and functional regeneration
    Biomaterials Science, 2020

  11. πŸ’§ Bioactive Molecules for Skin Repair and Regeneration: Progress and Perspectives
    Stem Cells International, 2019

  12. πŸ•ΈοΈ Concentrated Conditioned Medium-Loaded Silk Nanofiber Hydrogels with Sustained Release of Bioactive Factors To Improve Skin Regeneration
    ACS Applied Bio Materials, 2019

  13. 🚫 Arsenic trioxide inhibits the differentiation of fibroblasts to myofibroblasts through NFE2L2 and Smad2/3
    Journal of Cellular Physiology, 2019

  14. πŸ§ͺ Comparative Proteomic Analysis of the Effect of the Four-Herb Chinese Medicine ANBP on Promoting Mouse Skin Wound Healing
    The International Journal of Lower Extremity Wounds, 2017

  15. 🧠 Arsenic Trioxide Activate Transcription of Heme Oxygenase-1 via NFE2L2
    International Journal of Medical Sciences, 2015

  16. 🦴 Heme oxygenase-1 silencing increases sensitivity of osteosarcoma MG63 cells to arsenic trioxide
    Molecular and Cellular Biochemistry, 2014

Yuan Ma | Pharmacology | Best Researcher Award

Dr. Yuan Ma | Pharmacology | Best Researcher AwardΒ 

Dr. Yuan Ma, Hong Kong Baptist University, Netherlands.

Ma Yuan (Ph.D.) is a Research Assistant Professor at the Institute for Precision Medicine and Innovative Drug, Hong Kong Baptist University. He specializes in aptamer-based translational research and drug discovery, with expertise in nucleic acid chemistry, advanced organic chemistry, and tumor pharmacology. Dr. Ma earned his Ph.D. from Peking University, focusing on nucleoside lipid delivery for oligonucleotides. With over 34 publications, his research has significantly advanced cancer therapeutics and targeted drug delivery. His work continues to shape innovative biomedical applications.

Professional Profile

Scopus Profile

Orcid Profile

πŸŽ“ Early Academic Pursuits

Ma Yuan demonstrated an early passion for pharmaceutical sciences, embarking on his academic journey at Peking University. He earned a Bachelor of Science (2009-2013), majoring in organic chemistry, pharmacology, and pharmaceutical analysis. Advancing his expertise, he pursued a Master of Science (2013-2015) at the Stake Key Laboratory of Natural and Biomimetic Drugs, Peking University, focusing on DNA synthesis, medicinal chemistry, and tumor pharmacology. His master’s thesis explored the stability of D-/L-IsoNA modified siRNA under the mentorship of Prof. Zhenjun Yang. Driven by a deep interest in nucleic acid chemistry and drug development, Ma Yuan completed a Doctor of Philosophy (2015-2019) at the same institution, where he investigated novel nucleoside lipid delivery for single-stranded oligonucleotides, again under Prof. Zhenjun Yang.

πŸ’Ό Professional Endeavors

Building on his strong academic foundation, Ma Yuan transitioned into cutting-edge research and drug discovery. His professional career began as an Associate Research Fellow (2019-2020) at the Mengchao Hepatobiliary Hospital of Fujian Medical University, where he focused on nucleic acid-based diagnostics and treatment for primary liver cancer. He then moved to Hong Kong Baptist University, serving as a Postdoctoral Research Fellow (2020-2022) and later as a Research Assistant Professor (2022-Present) at the Institute for Precision Medicine and Innovative Drug. His work in aptamer-based translational research and drug discovery has made significant contributions to the field of targeted therapy and precision medicine.

πŸ”¬ Contributions and Research Focus On PharmacologyΒ 

Ma Yuan’s research is deeply embedded in the development of aptamer-based therapeutics, a revolutionary approach in cancer treatment and drug delivery. His work bridges organic chemistry, nucleic acid chemistry, and pharmacology, leading to breakthroughs in tumor-targeted therapies, nucleic acid-based drug modifications, and controlled drug release mechanisms. He has developed peptide aptamer-drug conjugates, explored hypoxia-potentiating agents, and innovated in bone anabolic aptamer therapies.

🌍 Impact and Influence

With a multidisciplinary approach spanning pharmaceutical chemistry, cancer therapy, and precision medicine, Ma Yuan’s research is shaping the future of personalized healthcare. His findings have contributed to improving drug efficacy, reducing side effects, and enhancing targeted delivery systems, significantly impacting the field of oncology and regenerative medicine.

πŸ“š Academic Citations & Publications

Ma Yuan has authored over 34 research papers in high-impact journals, including Acta Materia Medica, Cancer Letters, Journal of Medicinal Chemistry, and Molecular Therapy Nucleic Acids. His work has been cited extensively, reinforcing his influence in the field of nucleic acid drug discovery. His contributions as a first author, co-first author, and corresponding author highlight his leadership in scientific research.

πŸ… Awards and Honors

Throughout his career, Ma Yuan has received numerous accolades recognizing his excellence in pharmaceutical sciences and translational research. His research in aptamer-functionalized drug delivery systems and targeted cancer therapies has earned him global recognition.

πŸš€ Legacy and Future Contributions

As a pioneering researcher in nucleic acid-based therapies, Ma Yuan continues to push the boundaries of aptamer technology. His ongoing work in translational medicine, drug development, and biomolecular engineering promises to revolutionize cancer treatment, targeted drug delivery, and precision medicine. With his innovative approach and commitment to scientific advancement, he is set to leave a lasting impact on the future of personalized medicine.

Publications Top Notes

  1. Machine Learning-Powered, High-Affinity Modification Strategies for Aptamers πŸ§ πŸ”¬

    • Journal: Acta Materia Medica
    • Year: 2025 πŸ“…
  2. Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy πŸŽ―πŸ’Š

    • Journal: Pharmaceutics
    • Year: 2024 πŸ“…
  3. Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics 🦴🧬

    • Journal: Journal of Medicinal Chemistry
    • Year: 2024 πŸ“…
  4. Targeting Osteoblastic 11Ξ²-HSD1 to Combat High-Fat Diet-Induced Bone Loss and Obesity πŸ”βž‘οΈπŸ¦΄

    • Journal: Nature Communications
    • Year: 2024 πŸ“…
  5. Aptamer Functionalized Hypoxia-Potentiating Agent and Hypoxia-Inducible Factor Inhibitor Combined with Hypoxia-Activated Prodrug for Enhanced Tumor Therapy 🎯🦠

    • Journal: Cancer Letters
    • Year: 2024 πŸ“…
  6. Sclerostin Inhibition in Rare Bone Diseases πŸ¦΄πŸ’Š

    • Journal: Journal of Orthopaedic Translation
    • Year: 2024 πŸ“…
  7. Advancing Targeted Combination Chemotherapy in Triple Negative Breast Cancer: Nucleolin Aptamer-Mediated Controlled Drug Release πŸŽ―πŸ’Š

    • Journal: Journal of Translational Medicine
    • Year: 2024 πŸ“…
  8. Small RNAs in Cancer Therapy πŸ§¬πŸŽ—οΈ

    • Book Chapter: Interdisciplinary Cancer Research
    • Year: 2024 πŸ“…
  9. Aptamer AS411 Interacts with the KRAS Promoter/hnRNP A1 Complex and Shows Increased Potency Against Drug-Resistant Lung Cancer πŸ«πŸ’Š

    • Journal: RSC Medicinal Chemistry
    • Year: 2024 πŸ“…
  10. Design and Synthesis of Nucleotidyl Lipids and Their Application in the Targeted Delivery of siG12D for Pancreatic Cancer Therapy 🎯🩸

  • Journal: Biomedicine and Pharmacotherapy
  • Year: 2024 πŸ“…
  1. Unique Quinoline Orientations Shape the Modified Aptamer to Sclerostin for Enhanced Binding Affinity and Bone Anabolic Potential πŸ¦΄πŸ”¬
  • Journal: Molecular Therapy – Nucleic Acids
  • Year: 2024 πŸ“…
  1. The Modification Strategies for Enhancing the Metabolic Stabilities and Pharmacokinetics of Aptamer Drug Candidates πŸ§ͺ🩺
  • Book Chapter: Drug Metabolism and Pharmacokinetics
  • Year: 2024 πŸ“…
  1. Intracellular Sclerostin Plays a Vital Role in Tumor Progression and Metastasis in Triple-Negative Breast Cancer πŸŽ—οΈπŸ¦ 
  • Journal: Cancer Research
  • Year: 2024 πŸ“